Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Par pays $5.3 mil. to three Quad execs

Executive Summary

To complete acquisition of its injectables subsidiary. Par announced May 29 that it has finalized the acquisition of the 40% minority interest in Quad previously held by Quad's Senior VP-Secretary Raja Feroz, Senior VP-Treasurer Dulal Chatterji and Exec VP Asrar Burney. The agreement in principle was announced in April. The approximately $5.3 mil. transaction involves "$2 mil. in cash, $1 mil. in Quad notes payable over a four-year period, and 408,165 shares of Par stock" valued at $5.63 per share, Par said. The resignation of the three execs, upon the closing of the deal, clears the way for Par's new management to oversee the resolution of Quad's regulatory problems arising from the generic drug scandal.

You may also be interested in...

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts